We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $33.69, moving +0.78% from the previous trading session.

Hedge fund founder George Weiss filed a defamation suit in New York against Jefferies Financial (JEF), alleging the bank engaged in a “smear ...

Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...